Frailty and Heart Disease Fuel Each Other, and Routine Frailty Screening Could Break the Cycle

Frailty, a state of reduced physiological reserve and heightened vulnerability to stressors, affects 10-15% of community-dwelling older adults and up to 50% of hospitalized patients. Cardiovascular disease remains the world's leading killer, with roughly 20.5 million deaths in 2021. This review argues that the two conditions are not merely coincident but bidirectional. Frailty worsens cardiovascular outcomes, and CVD accelerates frailty. Traditional cardiovascular risk scores usually overlook frailty, which can lead to underestimated risk and undertreatment or mismatched treatment in vulnerable patients.

This is a narrative review of studies published between 2000 and 2025, identified through Google Scholar, PubMed and other databases using terms such as frailty, CVD, frailty assessment tools and multicomponent interventions. It does not describe a formal systematic protocol or quality appraisal. The authors first clarify terminology, separating frailty from sarcopenia, disability and comorbidity. They then map the shared biology. The portion of the text available for analysis covers inflammaging, mitochondrial dysfunction and oxidative stress, endothelial dysfunction, and neurohormonal dysregulation. The remaining sections were not available, so clinical findings below rely on the abstract.

On mechanisms, chronic low-grade inflammation (elevated IL-6 and TNF-α) drives atherosclerosis through NLRP3 inflammasome and Toll-like receptor signaling while promoting muscle catabolism and anabolic resistance. Canakinumab's IL-1β targeting is cited as clinical validation of the inflammatory pathway in CVD. Age-related mitochondrial decline lowers ATP production and raises reactive oxygen species, weakening both skeletal muscle and the heart and vasculature. Endothelial dysfunction (reduced nitric oxide, higher ADMA, impaired VEGF/NOS signaling and progenitor cell function) stiffens arteries and causes tissue hypoperfusion, which further worsens muscle energetics. Dysregulation of the HPA axis (an elevated cortisol-to-DHEA ratio), the renin-angiotensin-aldosterone system and the autonomic nervous system adds to this cycle. These pathways are linked to atrial fibrillation risk and poorer recovery after transcatheter aortic valve replacement.

Per the abstract, frailty prevalence varies by cardiovascular condition, from about 30% in coronary artery disease to 80% in heart failure. Frailty independently predicts adverse outcomes, with a 2.5-3.5-fold higher mortality risk. No gold-standard frailty tool exists for cardiovascular populations, although the Fried Phenotype and Clinical Frailty Scale are widely used. The authors favor multimodal interventions, particularly combined exercise and nutrition programs such as VIVIFRAIL and SPRINT-T, which improve physical function and frailty severity and are now endorsed in recent guideline recommendations for rehabilitation. Emerging strategies targeting shared pathways include senolytics (dasatinib plus quercetin), stem cell mobilization and angiogenic gene therapy.

The central implication is that frailty should be treated as a modifiable risk factor and assessed routinely in cardiovascular care to improve risk stratification and personalize treatment. Caveats are important. This is a narrative synthesis with likely selection bias, and much of the mechanistic evidence is observational or preclinical. The prevalence and mortality figures come from heterogeneous studies and assessment tools. The emerging therapies are still investigational, so their promise should not be read as proven benefit for frail cardiac patients.